Statistics from Altmetric.com
Mineralocorticoid receptor antagonists (MRAs) have been shown to decrease all-cause mortality and cardiovascular (CV) hospitalisation in patients with moderate-to-severe heart failure (HF) (ie, New York Heart Association (NYHA) class III and IV symptoms) with a reduced ejection fraction (EF)1 and in patients with acute myocardial infarction complicated by HF with systolic dysfunction.2 The aim of EMPHASIS-HF was to investigate the effects of eplerenone, in addition to evidence-based background therapy, on clinical outcomes in patients with mild HF (ie, NYHA class II symptoms) with a reduced EF.
Patients ≥55 years of age with NYHA functional class II symptoms, an EF ≤30%, treated with an ACE inhibitor/angiotensin receptor blocker and a β-blocker, and a history of CV-related hospitalisation within the past 6 months were enrolled. Patients …
Competing interests MG has received consulting fees from Bayer Schering Pharma AG, DebioPharm SA, Medtronic, Novartis Pharma AG, Otsuka Pharmaceuticals, Sigma Tau, Solvay Pharmaceuticals and Pericor Therapeutics. He is also a consultant for Abbott Labs, Astellas, Astra Zeneca, Bayer Schering Pharma AG, CorThera, Cytokinetics, DebioPharm SA, Errekappa Terapeutici (Milan, Italy), GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi Aventis, Sigma Tau, Solvay Pharmaceuticals. AA has no competing interests.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.